BRCA1 and neoplasm: That BRCA1 promoter hypermethylation does not predict response to platinum-based chemotherapy, even though it might contribute to tumor pathogenesis, is reflected in OS, PFS and PFS2 in our study, as no difference between the groups of patients with and without hypermethylation was observed.